In neonatal pneumonia, the surface activity of pulmonary surfactant is impaired and microorganisms may invade by passing the air-liquid interface. Previously, we have shown that addition of the antimicrobial peptide polymyxin B (PxB) to modified porcine surfactant (pSF) improves resistance to surfactant inactivation in vitro while antimicrobial activity of PxB is maintained. In this study, we investigated pSF/PxB in vivo. Neonatal near-term rabbits were treated with intratracheal pSF and/or PxB. Rabbits treated with only saline served as controls. Animals were ventilated with standardized tidal volumes and received ϳ10
P olymyxins are cyclic antimicrobial peptides derived from
Bacillus polymyxa with activity against a wide spectrum of Gram-negative bacteria including those considered to be multiresistant, e.g. Pseudomonas aeruginosa. Pharmacologically, rarely they are used for systemic application because nephrotoxic and neurotoxic effects have been described (1, 2) . However, polymyxins are topically administered. For treatment of chronic Gram-negative pneumonia, as in cystic fibrosis, polymyxin E or polymyxin B (PxB) is deposited in the lungs by inhalation.
Pulmonary surfactant is a lipoprotein complex aligning the alveolar air-liquid interface with the main function to reduce surface tension and thereby preventing alveolar collapse at end expiration (3) . In neonatal pneumonia and meconium aspiration syndrome (MAS), surfactant function can be inhibited by the presence of bacterial or meconium components. Thus, bacterial enzymatic break down of surfactant components, pulmonary inflammation, and reduced surfactant synthesis due to alveolar type II cell injury can be induced (4) . This may result in acute respiratory distress syndrome (ARDS). Surfactant replacement therapy is used in MAS, in neonatal pneumonia, and has been tested in ARDS in large clinical trials with promising effects in a subgroup with pneumonia (5) .
Our group previously found that addition of PxB to modified porcine surfactant (pSF) increases resistance to meconiuminduced surfactant inactivation in vitro while the antimicrobial function of PxB is maintained (6) . Thus, the combination of PxB and surfactant might be useful in clinical conditions such as neonatal Gram-negative pneumonia, MAS, or ARDS. It is unknown which effects a mixture of pSF/PxB may exert, whether pSF can be used as an effective vehicle for PxB or to which extent pSF/PxB improves lung compliance and enhances antimicrobial effects in vivo. The aim of this study was to address these questions in an animal model of neonatal Escherichia coli pneumonia.
MATERIALS AND METHODS

Bacteria.
After preincubation for 16 h at 37°C in a small volume of standardized bouillon (standard I; dissolved to 25 mg/L in water; Merck 7882, Merck, Darmstadt, Germany; composition: peptones 15 g/L; yeast extract 3 g/L; sodium chloride 6 g/L; D(ϩ) glucose 1 g/L), E. coli (ATTC 25922) reached a mid-logarithmic growth phase during incubation for 1 h in bouillon excess at 37°C (data of bacterial growth studies not shown). Then, a bacterial stock solution was prepared by centrifugation at 2500ϫ g for 10 min, twice washing the E. coli in saline and adjusting the bacterial concentration by means of the OD at 595 nm to ϳ10 8 /mL.
RESULTS
General data. Ninety-four animals were obtained, four animals were excluded due to air leaks or technical problems. Eight to 10 animals were randomly allocated to each treatment group. There was no statistical difference in body weight and lung/body weight within the treatment groups. Survival was low (22-60%) without statistical differences within the series.
Lung function. In general, compliance values were low and showed a wide range within the groups with a tendency to decrease over time (Tables 1 and 2 ). Compared with the compliance at 10 min, significantly reduced lung compliance was found after 4 h in the saline group and in the only PxB-treated group (Table 1) as well as in the control and the pSF group of the second series ( Table 2 ). Animals receiving pSF ϩ PxB showed no such tendency to reduce compliance over time. Compliance of pSF-Ϯ PxB-treated animals was slightly increased compared with controls (Tables 1 and 2) . After 1 and 4 h in the second series, compliance of pSF-ϩ PxB-treated animals was significantly increased (in group pSF ϩ PxB 0.25% at 60 min and 240 min; in group pSF ϩ PxB 0.5% at 60 min) compared with the control group (p Ͻ 0.05; Table 2 ).
Bacterial proliferation. Bacterial stock concentration of both series was similar with a mean of 3.2 ϫ 10 8 E. coli/mL in the first and 4.8 ϫ 10 8 E. coli/mL in the second series. At the end of the experiments, the bacterial count in lungs of animals receiving only PxB or pSF/PxB 1% was significantly reduced compared with control animals and rabbits receiving pSF ( Fig. 1 and 2) . Moreover, the bacterial load was reduced in a PxB concentration-dependent manner (Fig. 2) . In addition, the bacterial load of animals treated with pSF ϩ PxB Ն 0.5% was significantly reduced compared with pups treated with only pSF. In the second series, we found E. coli in the homogenate of the left kidney in 7 of 10 control animals and in 3 of 9 pSFtreated animals, but we found no bacterial contamination in any animal treated with pSF/PxB (p Ͻ 0.01).
Histology. Gross inspection of the lungs showed atelectasis and hemorrhage. Histologic analysis of both experimental series revealed improved expansion in animals receiving only pSF or pSF ϩ PxB (Table 3 ) with exception of the pSF/PxB 1% group of the second series (Table 3) . Airway epithelial necrosis was found in all treatment groups with a wide range and without any statistical difference. All animals receiving pSF ϩ PxB showed a significantly decreased level of inflammation (p Ͻ 0.05 vs control; Table 3 ). Inflammation was also found in animals receiving only saline without bacterial inoculation. Severe inflammatory tissue destruction was mainly found in controls and in pSF-treated animals, whereas moderate and mild inflammation, rarely prominent inflammation was found in pSF/PxB groups (Fig. 4) . The maximum grade of histologic inflammation was not found in the saline, the PxB 1% or the pSF ϩ PxB groups (Table 3 , Figs. 3C and D and 4).
DISCUSSION
We investigated the combined effects of PxB and pSF in an animal model of neonatal Gram-negative pneumonia. The rationale for this study was that neonates often receive both, antibiotics and surfactant, because respiratory failure directly after birth is common and it is difficult to distinguish between pneumonia and respiratory distress syndrome. The study was designed to use prophylactic intratracheal surfactant and/or PxB to assess efficacy of subsequent suppression of E. coli proliferation during a short period of mechanical ventilation. For additional comparison, early treatment studies of E. coli inoculation followed by administration of surfactant and/or PxB are needed. Early-onset neonatal sepsis with Gramnegative ampicillin-resistant E. coli is an emerging problem among very low birth weight infants (Ͻ1500ϫ g) since introduction of routine intrapartum antibiotic prophylaxis and prenatal screening for Group-B streptococci (10 -12) . PxB experiences attention in connection with emergence of multidrug-resistant Gram-negative bacteria (13, 14) . For early prevention of Gram-negative bacterial translocation by conducting airways and for prevention of bacterial inactivation of surfactant, a combined tracheal instillation of surfactant plus antibiotics could be of use.
The combination of surfactant and antibiotics may cause a change in surfactant and/or antimicrobial activity: van't Veen et al. (15, 16) found that antibiotics can affect the in vivo activity of bovine surfactant and that mice infected with Klebsiella pneumoniae showed increased survival after treatment with surfactant-tobramycin mixtures compared with animals treated with only surfactant or with only tobramycin. However, our previous studies demonstrated that addition of PxB to modified pSF increases resistance to surfactant inactivation and maintains antimicrobial activity of PxB (6) .
In this study, E. coli were nearly eradicated in animals which were treated with PxB or PxB plus surfactant. This could be caused by a homogenous PxB distribution resulting in an effective topical concentration of PxB. PxB can crosslink between the surfactant phospholipids (17, 18) and can be distributed with surfactant homogenously. The administered dose of PxB corresponds to the recommended daily doses of aerosolized PxB (2.5 mg/kg/d) (1), but the effective deposited dose may be increased compared with aerosolization when Ͻ5% of the nebulised drug reach the alveolar space. Furthermore, the PxB concentration used in our study (200 -800 g/mL) is 100-to 400-fold higher than the minimum in vitro inhibitory concentration against E. coli (ATCC 25922) of liposomal PxB, encapsulated in DPPC:Cholesterol, which was 2 Ϯ 0.5 g/mL (19) .
PxB has a high affinity to the lipid A moiety of endotoxin (lipopolysaccharide [LPS] ). In the absence of LPS in vitro, the surfactant/PxB preparations showed increased resistance to surfactant inactivation with albumin or meconium (5, 20) . However, in the present investigation, addition of PxB resulted only in an inconsistent improvement in compliance (Tables 1 and 2 ). Lung compliance can be used as an in vivo parameter of surface activity (3). The factors affecting surfactant activity and surfactant inactivation in this model are complex. The 29-d-old animals used in this study demonstrate poor compliance already in absence of E. coli, although they are near term (term gestation is 31 d) and lungs are relatively mature. To some extent poor compliance in this setting might be related to surfactant dilution of E. coli or saline with 5 mL fluid per kg body weight. A LPS challenge similar to our pneumonia model based on E. coli inoculation resulted in an inconsistent response in adult rats although identical doses of LPS were used (4). This could additionally contribute to the observed variability in compliance of animals that received E. coli. Furthermore, bacterial enzymes, which induce breakdown of surfactant components (21) , may contribute to surfactant inactivation.
Our histologic evaluation clearly shows an influx of inflammatory cells in lungs treated with E. coli regardless of addition of PxB. PxB causes cytolysis of Gram-negative bacteria by inducing pore formation in the membranes.
Thus, LPS and bacterial wall components still are present in the alveoli and act as a powerful proinflammatory agent inducing an increase of vascular permeability, neutrophilic alveolitis, septic shock, and ARDS (22, 23) . The intensity of systemic inflammatory and physiologic responses to intrapulmonary Gram-negative infection depends on the inoculum size and whether the bacteria are cleared from or proliferate in the lungs (24) . In addition, the inflammation also might be triggered to some degree by mechanical ventilation (25) . We also found inflammation and atelectasis in only saline-treated animals. Presumably, the atelectrauma of only saline-treated animals cannot be distinguished from the E. coli or endotoxin-induced inflammatory response. To reduce ventilator injury, the study was designed to use a low standardized V T of 6 -7 mL/kg body weight, which is recommended in ARDS (26) . However, we did not apply any PEEP. van Kaam (27) concluded from animal experiments that an open-lung ventilation strategy Histologically assessed alveolar air expansion that was semiquantitatively estimated by a five-grade scale (0 ϭ 0, 1 ϭ 1-25, 2 ϭ  26 -50, 3 ϭ 51-75, 4 ϭ 76 -100%), airway epithelial necrosis (0 ϭ absent, 1 ϭ mild, 2 ϭ moderate, 3 ϭ prominent) and grade of inflammation, which was estimated by using a five-grade scale (0 ϭ absent, 1 ϭ mild, 2 ϭ moderate, 3 ϭ prominent; 4 ϭ severe tissue destruction)
Treat Expansion Airway epithelial necrosis Inflammation
Animals treated with pSF and/or PxB 1% compared with control animals and animals receiving twice saline and no bacteria (saline) Saline
3 (1-4)* 0 (0 -3) 1 (0 -3)* † Animals treated with pSF Ϯ PxB (0.25-1%) compared with control animals Control 2 (1-3)
Results are given as median and range. * p Ͻ 0.05 vs control animals. † p Ͻ 0.05 vs pSF (Kruskal-Wallis test followed by Dunn's multiple comparison test). including PEEP in a model of GBS pneumonia is more important in attenuating inflammatory response than surfactant treatment. (33) . Curosurf treatment alone decreased mortality, pulmonary edema, and inflammation in spontaneously breathing rats with ARDS induced by intratracheal LPS injection (34) . Inflammatory effects may also be reduced by surfactant by suppressing cytokine secretion, mitogen-driven proliferation, neutrophil influx, and immunoglobulin production (35, 36) . In this study, we found a high rate of early death in all treatment groups. In a similar model of GBS pneumonia in near-term rabbits, in which animals were ventilated with higher V T (8 -10 mL/kg) and a prolonged inspiration time, survival was increased (37) . In comparison, a high rate of early death due to GBS pneumonia was found in newborn piglets with conventional ventilation compared with openlung ventilation (28) .
In this study, PxB was given topically onto the inner surface of the lung. Although PxB does not appear to be reabsorbed by the skin or gastrointestinal mucosa (1), it might be resorbed through inflammatory lesions of the conducting airways. We did not measure PxB reabsorption in animals. Omri et al. (19) used a similar preparation in which PxB was encapsulated in liposomes of DPPC and cholesterol, for topical pulmonary treatment in a rat model of chronic Gram-negative pneumonia and found decreased inflammatory lung injury and nondetectable levels of PxB in serum and the kidney, although PxB is primarily excreted through the kidney. Liposomal formulations delivered into the lung might cause sustained drug release and thereby low serum and tissue levels of PxB. Thus, the risk of toxic effects might be less compared with treatment with PxB alone (19) .
The main result of this study was that intratracheal administration of pSF/PxB mixtures exerts potent antibacterial effects. Surfactant/PxB mixtures reduced bacterial translocation to the systemic circulation and mitigated the inflammatory reaction in the lungs. We speculate that by optimizing the ventilation strategy in our model, the level of inflammation could be further decreased and early death might be prevented.
In conclusion, intratracheal instillation of pSF/PxB mixtures in neonatal near-term rabbits reduces bacterial growth in the lungs and prevents bacterial sepsis without exerting negative effects on lung function. This treatment cannot prevent a pulmonary inflammatory response because endotoxin exposure is still present. Further studies investigating mature and immature neonates with Gram-negative pneumonia and studying physiologic and toxicological data (as PaO 2 , blood gas analysis, PxB elimination) during open-lung ventilation are needed, before the safety of a pSF/PxB combination can be assessed in a clinical setting.
